Clinical trial
Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient…
NCT00156143 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00156143 |
|---|---|
| Title | Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents |
| Official title | GH Therapy in Partial GHD Adolescents : Evaluation of Efficacy Based on Body Composition and Comparison of 2 Different Doses of Genotonorm®. Open-Label, Randomised, Comparative, Controlled, Parallel-Group, Multi-Center Phase IIIB Clinical Trial. |
| Acronym | TAUBER |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Growth Hormone Deficiency |
| Intervention type | Procedure |
| Interventions | Blood sample, Radiography |
| Enrollment | 90 |
| Start date | Apr 1, 2002 |
| Completion | Apr 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Jul 30, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: